Healthcare Active Stocks: Johnson & Johnson (NYSE:JNJ), Endo International (NASDAQ:ENDP), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY)

FB Nasdaq FB Facebook

Johnson & Johnson (NYSE: JNJ) has inked a global licensing deal with the privately held Aduro BioTech for developing new therapies to treat prostate cancer. According to the oncology deal, the private company granted Janssen Biotech, a division of Johnson & Johnson, the exclusive license to certain candidates specifically engineered for the treatment of prostate cancer on the basis of Aduro’s proprietary live-attenuated double-deleted (LADD) immunotherapy platform. Johnson & Johnson (NYSE:JNJ) stock performance was 0.69% in last session and finished the day at $101.46. Traded volume was 5.97million shares in the last session and the average volume of the stock remained 7.75million shares. The beta of the stock remained 0.57. Johnson & Johnson (NYSE:JNJ) insider ownership is 0.02%.

Endo International PLC (NASDAQ:ENDP), a U.S. drug maker formerly based in Malvern, PA, agreed to acquire Paladin Labs, Inc., a Montreal-based company, for $1.6 billion. The acquisition resulted in an inversion transaction whereby a newly-created Irish holding company (Ireland having much lower tax rates) ending up owning both Endo and Paladin. Endo International PLC (NASDAQ:ENDP) dropped -1.13 percent to $70.59 Friday on volume of 7.25million shares. The intra-day range of the stock was $70.52 to $72.55. Endo International PLC (NASDAQ:ENDP) has a market capitalization of $10.71billion.

Drug makers are under fire as the $84,000 price tag on a new hepatitis medicine has galvanized the debate over prescription drug costs. At the heart of the latest controversy is Sovaldi, a miracle drug introduced this year and manufactured by Gilead Sciences, Inc. (NASDAQ:GILD), that cures 90 percent of Hepatitis C cases, a condition that affects 3 million people. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on May 30, 2014 reported a decrease of -1.06% to the closing price of $81.21. Its fifty two weeks range is $46.70 -$84.88. The total market capitalization recorded $124.71billion. The overall volume in the last trading session was 11.06million shares. In its share capital, GILD has 1.54billion outstanding shares.

Competitors such as Merck Squibb Co (NASDAQ:MRK) and Bristol-Myers Squibb appear to have more promising pipelines, and that could impact Pfizer in the near future. On Friday, shares of Bristol-Myers Squibb Co (NYSE:BMY) advanced 0.44% to close the day at $49.74. Company return on investment (ROI) is 10.70% and its monthly performance is recorded as -0.70%. Bristol-Myers Squibb Co (NYSE:BMY) quarterly revenue growth is -6.85%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone